Publicaciones en colaboración con investigadores/as de Universidad de Alcalá (22)

2023

  1. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  2. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 79-92

  3. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)

    Gut, Vol. 72, Núm. 8, pp. 1581-1591

2021

  1. A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt

    European journal of gastroenterology & hepatology, Vol. 33, Núm. 1S Suppl 1, pp. e587-e593

2020

  1. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19

    The Journal of infectious diseases, Vol. 222, Núm. 5, pp. 726-733

  2. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis

    Clinical Infectious Diseases, Vol. 71, Núm. 10, pp. 2726-2729

2019

  1. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

  2. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

    The Lancet, Vol. 393, Núm. 10181, pp. 1597-1608

2017

  1. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

    Gastroenterology, Vol. 153, Núm. 5, pp. 1273-1283.e1

2013

  1. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial

    Hepatology, Vol. 57, Núm. 3, pp. 1153-1162

  2. Liver diseases

    Gastroenterologia y Hepatologia, Vol. 31, Núm. SUPPL.4, pp. 93-104

  3. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis

    Scandinavian Journal of Gastroenterology, Vol. 48, Núm. 4, pp. 487-495

2007

  1. The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis

    Gut, Vol. 56, Núm. 2, pp. 259-264

  2. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: A meta-analysis

    American Journal of Gastroenterology, Vol. 102, Núm. 5, pp. 1116-1126

2003

  1. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT

    Hepatology, Vol. 37, Núm. 6, pp. 1260-1266

2002

  1. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis

    Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology, Vol. 21, Núm. 4, pp. 169

  2. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis

    Hepatology, Vol. 35, Núm. 3, pp. 609-615

  3. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis

    Hepatology, Vol. 36, Núm. 6, pp. 1367-1373

2001

  1. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers

    Gastroenterology, Vol. 121, Núm. 4, pp. 908-914

  2. Liver, pancreas, and biliary tract: Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis

    Gastroenterology, Vol. 121, Núm. 2, pp. 382-388